Introduction
Succinate (succinic acid in blood pH) has only been considered for many decades as an intermediate metabolite of the tricarboxylic acid (TCA) cycle. During aerobic respiration, succinate is oxidized to fumarate, donating reducing equivalents. The reaction is catalyzed by succinate dehydrogenase (SDH), an enzyme complex located in the inner mitochondrial membrane that participates in both the TCA cycle and electron transport chain. SDH is composed of four nuclearly encoded subunits whose structure and genes have mostly been conserved through evolution. Hans Adolf Krebs team noticed some intermediates, including succinate, could accumulate in the interstitial space during liver ischemia (1) . During ischemia, succinate can be produced by reduction of fumarate (a purine nucleotide cycle metabolite) via the reverse action of SDH. Succinate is then secondarily secreted from the cells into the blood stream (2) .
Many studies have shown that succinate has several functions beyond participating in the TCA cycle, of which some are mediated via a G protein-coupled succinate receptor (GPR91) (3) .
Through GPR91, succinate may have hormone-like actions in blood cells as well as fat, liver, heart, retina, and kidney tissues (4) . For instance, in response to retinal ischemia, succinate plays an important role in the development of new blood vessels via GPR91 and subsequent modulation of VEGF release by retinal ganglion neurons (5).
Beyond cell functions described above, succinate and a few other TCA cycle intermediates were found to contribute to carcinogenesis (6) . Recently, germline and somatic mutations in an additional three TCA cycle enzymes, fumarate hydratase (FH), malate dehydrogenase type 2 (MDH2), and isocitrate dehydrogenase (IDH) were identified in diverse cancers, which suggest metabolic alterations as the underlying hallmark of cancer. These mutations cause disruption of the TCA cycle and accumulation of TCA cycle intermediates, ultimately altering various functions and the epigenome of cancer cells. These so-called oncometabolites were found to act as competitors of 2-oxoglutarate-dependent dioxygenases, which are involved in a broad spectrum of pathways such as hypoxic response, immune system dysfunction, and epigenetic reprogramming (7).
Pheochromocytomas and paragangliomas (PPGL) are tumors associated with TCA cycle defects (8) . The most common cause of hereditary PPGL is SDH deficiency and accumulation of highly elevated levels of succinate. These tumors, unlike IDH-mutants tumors (9) , are highly glucose avid (8 (10) . This finding is attributed to activation of hypoxia signaling (8) and is in discordance with several experimental studies that have failed to identify increased glycolysis (11) (12) (13) (14) (15) . Interestingly, neuroblastoma cell lines (a neural-crest tumor model similar to PPGL) with SDHB mutations were even found to have a paradoxical decrease in glucose uptake compared to wild-type cells, despite an increased growth rate and invasiveness (16) . These effects were even more pronounced in the presence of human fibroblasts in co-culture experiments, indicating a possible metabolic cooperation between stroma and cancer cells (17) . Primary human fibroblasts exhibit an increased glucose uptake when they are co-cultured with wild-type cells, and an even greater uptake when co-cultured with SDHB- In vitro evaluation of cell viability PET images were acquired 40 min after injection on a Mediso NanoPET/CT under 1.5% isoflurane anesthesia. ROI quantification was performed on reconstructed PET/CT images, corrected by a tumor volume and pondered by animal weight.
At the end of the procedure, animals were euthanized with a lethal dose of pentobarbital, and the tumors were then explanted, stored in PFA4%, sliced, and directly exposed for 30 seconds to medium-sensitive phosphorimaging plates. Signals were analyzed by densitometry 
of succinate
Fourteen days after tumor engraftment, the xenografted mice from the second group were injected with a 1 nmol/µL succinate solution or with PBS (10 µL in the tumor, n=3 per condition)
MBq/50µL, i.v.) was performed 3 hours after the last succinate injection. The xenografted mice from the third group were injected with a 1 nmol/µL succinate solution or with PBS (10 µL in the fluorocholine injection (5-10 MBq/50µL, i.v.) was performed 3 hours after the last succinate injection. PET images were acquired beginning with the injection on a Mediso NanoPET/CT camera under 1.5% isoflurane anesthesia. PET images were reconstructed in dynamic mode with 10 frames of 1 minute, then 6 frames of 5 minutes followed by one 20-minutes frame. ROI quantification was performed on PET/CT images, corrected by a tumor volume.
injections of succinate
Twelve BALB/c mice were injected in the right quadriceps femoris muscle with succinate (10µL from a 1 nmol/µL solution) and in the left quadriceps femoris muscle with fumarate (10µL different groups 3 hours after the last succinate injection. PET images were acquired beginning with the injection on a Mediso NanoPET/CT camera under 1.5% isoflurane anesthesia. PET images were reconstructed in dynamic mode with 10 frames of 1 minutes, 6 frames of 5 minutes followed by one 20-minutes frame.
LASER-Doppler perfusion imaging (Perimed) was used to assess hind limb blood flow as expressed as a ratio of succinate-treated limb to PBS-or fumarate-treated limb blood flow.
Immunohistochemistry
To assess whether the increased uptake was due to GLUT1 overexpression after succinate treatment, GLUT1 immunohistochemistry (GLUT-1, Rabbit Polyclonal Antibody, Thermo Scientific, RB-9052-P, dilution 1:200) was performed on HT-29 tumors and HUVECs treated with succinate, fumarate, or PBS. The immunoreactivity of GLUT1 was visually scored by a pathologist blinded to the study groups.
Statistics
Comparison of in vitro cellular uptake and cell viability were analyzed by 1-way ANOVA 0014, n=3, Fig. 1A, Suppl Fig 1) and autoradiography (P=0. 0124, n=3, Fig. 1B) . Autoradiography resolution did not allow us to discriminate the effects of succinate in the different compartments in vivo. To test whether tracer uptake was linked to glucose metabolism and not related to increased blood flow or increased capillary permeability induced by succinate, we performed head-to-head comparison between observed in both groups (P=0.6088, n=3, Fig. 1D ). 
Succinate increases [ 18 F]-FDG uptake by endothelial cells, but not in tumor cells or and retention

Succinate increases in vivo [ 18 F]-FDG uptake and retention by connective tissue
To test whether a modification in uptake pattern of connective tissue could produce the changes on PET imaging, we evaluated the effects of intramuscular administration of succinate in mice.
muscle compared to the contralateral muscle injected with either PBS (P=0.0162, n=3) or fluorocholine uptake compared to the contralateral muscle injected with either PBS (P=0.6173, n=3) or fumarate (P=0.92303, n=3, Fig. 3B ). Finally, no difference on hind limb blood flow was observed on LASER-Doppler (P=1.000, n=3 and P=0.7500, n=3 respectively, Fig. 3C ).
GLUT1 Immunohistochemistry
GLUT1 expression quantification did not significantly differ between study groups in HUVECs or HT-29 tumors (in both epithelial and stromal compartments) ( Suppl Fig 2 and 3) .
Discussion
It is now evident that succinate should not only be viewed as a metabolite donor in the TCA cycle, but also as a signaling molecule with hormone-like functions, which could play a vital role during various pathophysiological conditions such as ischemia (4) (42, 43) . Notably, the increased glucose uptake in endothelial cells is not due to increased GLUT1 expression.
However, this could be due to the involvement of other glucose transporters and/or increased activity of intracellular hexokinases (44) . Finally, it would be interesting to use GPR91
antagonists or nitric oxide (NO) signaling modulation to study the signaling pathway involved in succinate-induced glucose uptake by endothelial cells (45, 46) . If so, this concept could propose a novel therapeutic approach on starving PPGL via inhibition of GPR91 or NO signaling.
